Rani-Logo.jpg
Rani Therapeutics to Participate in September Investor Conferences
September 03, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics to Participate in August Investor Conferences
July 29, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
July 22, 2024 08:30 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
June 24, 2024 07:00 ET | Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...
Rani-Logo.jpg
Rani Therapeutics to Participate in May Investor Conferences
May 14, 2024 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
May 06, 2024 16:05 ET | Rani Therapeutics, LLC
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis...
Rani-Logo.jpg
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
March 15, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Pharmacokinetics of Ustekinumab (CT-P43) Oral (RT-111) vs SC Injection
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
February 05, 2024 08:00 ET | Rani Therapeutics, LLC
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...
Peak Decreases in Body Weights
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
December 14, 2023 08:00 ET | Rani Therapeutics, LLC
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform...
Adalimumab 11mg via RaniPill HC vs Adalimumab Biosimilar 5mg via Subcutaneous Injection
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
November 08, 2023 16:05 ET | Rani Therapeutics, LLC
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of...